Skip to main content
. 2020 Jul;9(7):4111–4120. doi: 10.21037/tcr-20-1451

Table 7. Clinical response according to LMR-week 6 for NSCLC patients.

Response Number (N=20, %) Low LMR-week 6 (N=13, 65%) High LMR-week 6 (N=7, 35%)
CR 1 (5.0) 0 (0.0) 1 (14.3)
PR 4 (20.0) 1 (7.7) 3 (42.9)
SD 1 (5.0) 0 (0.0) 1 (14.3)
PD 14 (70.0) 12 (92.3) 2 (28.6)

NSCLC, non-small-cell lung cancer; N, number; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; LMR-week 6, lymphocyte-to-monocyte ratio 6 weeks after the start of PD-1 inhibitors.